» Articles » PMID: 11436421

Cidofovir in the Treatment of HPV-associated Lesions

Overview
Specialty General Medicine
Date 2001 Jul 5
PMID 11436421
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The acyclic nucleoside phosphonate cidofovir (CDV) has proved efficacious in the treatment of different clinical manifestations of HPV-induced epithelial cell proliferation. Local intratumor injections of CDV in an immunocompetent patient with hypopharyngeal/esophageal papillomatous lesions, PCR-positive for HPV types 16 and 18, resulted in a complete regression of the tumor. Similarly, CDV, injected locally in patients with recurrent respiratory papillomatosis resulted in complete disappearance or partial remission of the lesions. Recently, a child with disseminated respiratory papillomatosis was treated with systemic (intravenous) CDV, resulting in stabilization of the disease. In addition, CDV topical gel has been successfully used for the treatment of severe, relapsing anogenital HPV lesions and cervical intraepithelial neoplasia (CIN) grade III. In vitro, treatment of HPV-positive cells (compared to normal primary human keratinocytes) with CDV has resulted in a concentration- and time-dependent inhibition of cell proliferation. Different parameters of apoptosis, i.e., (i) induction of CPP32 (caspase-3) protease activity, (ii) translocation of phosphatidylserine (PS) from the inner part of the plasma membrane to the outer layer, (iii) disintegration of the nuclear matrix protein (NMP), (iv) DNA fragmentation, (v) number of cells in apoptotic phase following cell cycle analysis, showed that the mechanism of cell death following treatment with CDV is based on apoptosis. Induction of apoptosis in HPV-positive cells by CDV was associated with accumulation of the tumor suppressor proteins p53 and pRb and the cyclin-dependent kinase inhibitor p21/WAF-1. In conclusion, CDV has great potential in the treatment of severe HPV-induced proliferative lesions, either laryngeal, esophageal/pharyngeal or genital. As CDV has proved able to induce apoptosis, in a time- and concentration-dependent manner, in a number of HPV-positive cell lines, the regression of papillomatous tumors observed with CDV in patients, may be due, at least in part, to the induction of apoptosis.

Citing Articles

Unraveling the Complex Nexus of Human Papillomavirus (HPV) in Extragenital Keratinocyte Skin Tumors: A Comprehensive Analysis of Bowen's Disease and In Situ Squamous-Cell Carcinoma.

Conforti C, Retrosi C, Agozzino M, Dianzani C, Nardon E, Oliveri A J Clin Med. 2024; 13(4).

PMID: 38398404 PMC: 10889444. DOI: 10.3390/jcm13041091.


Efficacy of commercially available biological agents for the topical treatment of cervical intraepithelial neoplasia: a systematic review.

Mutombo A, Simoens C, Tozin R, Bogers J, Van Geertruyden J, Jacquemyn Y Syst Rev. 2019; 8(1):132.

PMID: 31174598 PMC: 6555029. DOI: 10.1186/s13643-019-1050-4.


Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.

Dadar M, Chakraborty S, Dhama K, Prasad M, Khandia R, Hassan S Front Immunol. 2018; 9:2478.

PMID: 30483247 PMC: 6240620. DOI: 10.3389/fimmu.2018.02478.


Antiviral Drugs for EBV.

Pagano J, Whitehurst C, Andrei G Cancers (Basel). 2018; 10(6).

PMID: 29899236 PMC: 6025560. DOI: 10.3390/cancers10060197.


New molecular targets against cervical cancer.

Duenas-Gonzalez A, Serrano-Olvera A, Cetina L, Coronel J Int J Womens Health. 2014; 6:1023-31.

PMID: 25525394 PMC: 4266260. DOI: 10.2147/IJWH.S49471.